Mesoporous silica nanoparticles act as a self-adjuvant for ovalbumin model antigen in mice

Mahony, Donna, Cavallaro, Antonino S., Stahr, Frances, Mahony, Timothy J., Qiao, Shi Zhang and Mitter, Neena (2013) Mesoporous silica nanoparticles act as a self-adjuvant for ovalbumin model antigen in mice. Small, 9 18: 3138-3146. doi:10.1002/smll.201300012

Author Mahony, Donna
Cavallaro, Antonino S.
Stahr, Frances
Mahony, Timothy J.
Qiao, Shi Zhang
Mitter, Neena
Title Mesoporous silica nanoparticles act as a self-adjuvant for ovalbumin model antigen in mice
Journal name Small   Check publisher's open access policy
ISSN 1613-6810
Publication date 2013-09-23
Year available 2013
Sub-type Article (original research)
DOI 10.1002/smll.201300012
Volume 9
Issue 18
Start page 3138
End page 3146
Total pages 9
Place of publication Weinheim Germany
Publisher Wiley - V C H Verlag GmbH & Co. KGaA
Language eng
Formatted abstract
Immunization to the model protein antigen ovalbumin (OVA) is investigated using MCM-41 mesoporous silica nanoparticles as a novel vaccine delivery vehicle and adjuvant system in mice. The effects of amino surface functionalization and adsorption time on OVA adsorption to nanoparticles are assessed. Amino-functionalized MCM-41 (AM-41) shows an effect on the amount of OVA binding, with 2.5-fold increase in binding capacity (72 mg OVA/g AM-41) compared to nonfunctionalized MCM-41 (29 mg OVA/g MCM-41). Immunization studies in mice with a 10 μg dose of OVA adsorbed to AM-41 elicits both antibody and cell-mediated immune responses following three subcutaneous injections. Immunizations at a lower 2 μg dose of OVA adsorbed to AM-41 particles results in an antibody response but not cell-mediated immunity. The level of antibody responses following immunization with nanoformulations containing either 2 μg or 10 μg of OVA are only slightly lower than that in mice which receive 50 μg OVA adjuvanted with QuilA, a crude mixture of saponins extracted from the bark of the Quillaja saponaria Molina tree. This is a significant result, since it demonstrates that AM-41 nanoparticles are self-adjuvanting and elicit immune responses at reduced antigen doses in vivo compared to a conventional delivery system. Importantly, there are no local or systemic negative effects in animals injected with AM-41. Histopathological studies of a range of tissue organs show no changes in histopathology of the animals receiving nanoparticles over a six week period. These results establish the biocompatible MCM-41 silica nanoparticles as a new method for vaccine delivery which incorporates a self-adjuvant effect. Amino-functionalized mesoporous silica nanoparticles have a high adsorption capacity for ovalbumin. Ovalbumin-bound nanoparticles are used as a delivery system in mice to test their efficacy. Immunization results in both cell-mediated and humoral immunity. The nanoparticles not only act as a protein carrier but also as an effective adjuvant. These results establish mesoporous silica nanoparticles as a viable vaccine delivery vehicle.
Keyword adjuvants
drug delivery
mesoporous silica nanoparticles
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 39 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 42 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Fri, 29 Nov 2013, 05:45:01 EST by System User on behalf of Qld Alliance for Agriculture and Food Innovation